Levormeloxifene

Levormeloxifene

Levormeloxifene

Chemical compound


Levormeloxifene (INNTooltip International Nonproprietary Name; developmental code names 6720-CDRI, NNC-460020) is a selective estrogen receptor modulator (SERM) which was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed.[1] The development was stopped because of a high incidence of gynecological side effects during clinical trials.[2] Levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive.

Quick Facts Clinical data, Other names ...

See also


References

  1. "Levormeloxifene - AdisInsight".
  2. Ravn P, Nielsen TF, Christiansen C (2006). "What can be learned from the levormeloxifene experience?". Acta Obstet Gynecol Scand. 85 (2): 135–42. doi:10.1080/00016340500345691. PMID 16532904. S2CID 12872469.



Share this article:

This article uses material from the Wikipedia article Levormeloxifene, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.